Grundläggande statistik
| CIK | 1521420 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Proto Script Pharmaceutical Corp.
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| March 29, 2018 |
PSCR / Proto Script Pharmaceutical Corp. FORM NT 10-K NOTICE OF LATE ANNUAL FILING Form NT 10-K Notice of Late Annual Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 8, 2018 |
PSCR / Proto Script Pharmaceutical Corp. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For Quarter Ended: September 30, 2017 Commission File Number 333-175146 PROTO SCRIPT PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Nevada 99-0363803 (State or other jurisdiction (I.R.S. Employer of in |
|
| January 17, 2018 |
PSCR / Proto Script Pharmaceutical Corp. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For Quarter Ended: June 30, 2017 Commission File Number 333-175146 PROTO SCRIPT PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Nevada 99-0363803 (State or other jurisdiction (I.R.S. Employer of incorpo |
|
| November 22, 2017 |
PSCR / Proto Script Pharmaceutical Corp. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For Quarter Ended: March 31, 2017 Commission File Number 333-175146 PROTO SCRIPT PHARMACEUTICAL CORP. (Exact name of registrant as specified in its charter) Nevada 99-0363803 (State or other jurisdiction (I.R.S. Employer of incorp |
|
| October 27, 2017 |
Proto Script Pharmaceutical FORM 8-K (Current Report/Significant Event) pscr8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) off The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2017 PROTO SCRIPT PHARMACEUTICAL CORP. (Exact name of registrant as specified in charter) Nevada 333-175146 99-0363803 (State or other jurisdiction of incorpor |
|
| October 27, 2017 |
Letter from KLJ dated October 27, 2017 regarding change in certifying accountant pscrex161.htm EXHIBIT 16.1 October 27, 2017 Securities and Exchange Commission 450 Fifth Street N.W. Washington, DC 20549 We have read the statements of Proto Script Pharmaceutical Corp., pertaining to our firm included under Item 4.01 of Form 8-K dated October 25, 2017 and agree with such statements as they pertain to our firm. Sincerely, /s/ KLJ & Associates, LLP 5201 Eden Avenue Suite 300 Edina |
|
| October 19, 2017 |
pscr8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) off The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2017 PROTO SCRIPT PHARMACEUTICAL CORP. (Exact name of registrant as specified in charter) Nevada 333-175146 99-0363803 (State or other jurisdiction of incorpora |
|
| October 19, 2017 |
PSCR / Proto Script Pharmaceutical Corp. FORM 10-K/A (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 x ANNUAL REPORT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 333-175146 PROTO SCRIPT PHAR |
|
| September 20, 2017 |
PSCR / Proto Script Pharmaceutical Corp. FORM 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 333-175146 PROTO SCRIPT PHARMACEUTICAL CORP. ( |
|
| March 31, 2017 |
Proto Script Pharmaceutical NOTICE OF LATE FILING Notice of Late Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 15, 2017 |
Proto Script Pharmaceutical FORM 8-K CURRENT REPORT (Current Report/Significant Event) Form 8-K Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 6, 2017 |
Proto Script Pharmaceutical FORM 10-Q QUARTERLY REPORT (Quarterly Report) Form 10-Q Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 7, 2016 |
Proto Script Pharmaceutical FORM 10-Q/A AMENDED QUARTERLY REPORT (Quarterly Report) Form 10-Q/A Amended Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 18, 2016 |
Proto Script Pharmaceutical FORM 10-Q QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q X . QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 . TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE EXCHANGE ACT For the transition period from to Commission File Number: 333-175146 PROTO SCRIPT PHARMACEUTICAL CORP. (Name of Small Bu |
|
| November 17, 2016 |
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Form 8-K Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 17, 2016 |
Proto Script Pharmaceutical ESP SEC Response Letter PROTO SCRIPT PHARMACEUTICAL CORP. 9830 6th Street, Suite 103 Rancho Cucamonga, California 91730 November 17, 2016 Mr. Larry Spirgel, Assistant Director United States Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Re: Proto Scrip Pharmaceutical Corp. Amendment No. 2 to Form 8-K Amendment No. 1 to Form 10-K for Fiscal Y |
|
| November 7, 2016 |
Proto Script Pharmaceutical FORM 10-K/A AMENDED ANNUAL REPORT (Annual Report) Form 10-K/A Amended Annual Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 7, 2016 |
Proto Script Pharmaceutical FORM 8-K/A2 CURRENT REPORT (Current Report/Significant Event) Form 8-K/A2 Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 7, 2016 |
Exhibit 10.2 Supply Agreement April 28, 2016 TERRY MOFFIT PROTO-SCRIPT PHARMACEUTICALS CORP 2221 E WINSTON RD STE O ANAHEIM, CA 92806-5540 Re: Contract Number: 23-3834457 Dear TERRY MOFFIT: For your records, please reference the fully executed Contract for the Round 2 Recompete of the Medicare Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) Competitive Bidding Program. Thi |
|
| November 7, 2016 |
Exhibit 99.2 Yanex Pro-Forma FS YANEX GROUP, INC. Pro-Forma Consolidated Financial Statements For the period ended March 31, 2016 (unaudited prepared by management) Pro-Forma Balance Sheets as of March 31, 2016 2 Pro-Forma Statements of Operations for the twelve months ended March 31, 2016 3 Notes to the Pro-Forma Financial Statements 4 YANEX GROUP, INC. Pro-Forma Balance Sheets (unaudited) Yane |
|
| November 4, 2016 |
Proto Script Pharmaceutical ESP SEC Response Letter PROTO SCRIPT PHARMACEUTICAL CORP. 9830 6th Street, Suite 103 Rancho Cucamonga, California 91730 November 4, 2016 Mr. Larry Sprigel, Assistant Director Kathleen Krebs, Special Counsel Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Re: Yanex Group, Inc. Amendment No. 1 to Current Report on Form 8-K Filed September 9, 20 |
|
| October 14, 2016 |
Proto Script Pharmaceutical FORM 8-K CURRENT REPORT (Current Report/Significant Event) Form 8-K Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 6, 2016 |
Exhibit 3.01b Articles of Merger |
|
| October 6, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) off The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2016 YANEX GROUP, INC. (Exact name of registrant as specified in charter) Nevada 333-175146 99-0363803 (State or other jurisdiction of incorporation) (Commission File N |
|
| October 6, 2016 | ||
| October 6, 2016 |
EX-3.01C 4 f8k100516ex3z01c.htm EXHIBIT 3.01C CERTIFICATE OF CHANGE |
|
| September 21, 2016 |
Material Modification to Rights of Security Holders, Financial Statements and Exhibits Form 8-K Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| September 21, 2016 |
Exhibit 3.1 Certificate of Designation |
|
| September 8, 2016 |
Exhibit 10.2 Supply Agreement |
|
| September 8, 2016 |
Exhibit 99.1 Proto-Script Financial Statements PROTO-SCRIPT PHARMACEUTICALS, CORP. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED DECEMBER 31, 2015 AND 2014 AND FOR THE THREE MONTHS ENDED MARCH 31, 2016 AND 2015 Contents Page Report of Independent Registered Public Accounting Firm 2 Consolidated Financial Statements: Consolidated Balance Sheets as of March 31, 2016 (unaudited) Dece |
|
| September 8, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/Amendment No. 1 CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 29, 2016 YANEX GROUP, INC. (Exact name of registrant as specified in its charter) Nevada 333-175146 99-0363803 (State or other jurisdiction (Commission File Numbe |
|
| September 8, 2016 |
YANEX GROUP, INC. Pro-Forma Consolidated Financial Statements For the period ended March 31, 2016 (unaudited prepared by management) Pro-Forma Balance Sheets as at December 31, 2015 2 Pro-Forma Statements of Operations for the three months ended March 31, 2016 3 Pro-Forma Statements of Operations for the twelve months ended December 31, 2015 4 Notes to the Pro-Forma Financial Statements 5 YANEX |
|
| September 8, 2016 |
Proto Script Pharmaceutical ESP September 8, 2016 Mr. Larry Sprigel, Assistant Director Kathleen Krebs, Special Counsel Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Re: Yanex Group, Inc. Form 8-K Filed July 5, 2016 File No. 333-175146 Dear Mr. Sprigel and Ms. Krebs: Yanex Group, Inc., an Nevada corporation (the Company), has received and reviewed your letter dated |
|
| August 19, 2016 |
Yanex Group FORM 10-K ANNUAL REPORT (Annual Report) Form 10-K Annual Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 19, 2016 |
Yanex Group FORM 10-K ANNUAL REPORT (Annual Report) Form 10-K Annual Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 17, 2016 |
Proto Script Pharmaceutical ESP SEC Letter August 15, 2016 VIA EDGAR SUBMISSION Ms. Kathleen Krebs Special Counsel United States Securities and Exchange Commission Division of Corporation Finance Washington D.C. 20549 Re: Yanex Group, Inc. Form 8-K Filed July 5, 2016 File No. 333-175146 Dear Ms. Krebs: We are in receipt of your comment letter dated July 28, 2016, regarding Yanex Group, Inc.'s July 5, 2016, Form 8-K filing. We ar |
|
| July 12, 2016 |
Yanex Group DEFINITIVE 14C INFORMATION STATEMENT Definitive 14C Information Statement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 5, 2016 |
Exhibit 99.2 Yanex Pro-Forma Financial Statements YANEX GROUP, INC. Pro-Forma Consolidated Financial Statements For the period ended March 31, 2016 (unaudited ? prepared by management) Pro-Forma Balance Sheets 2 Pro-Forma Statements of Operations for the twelve months ended March 31, 2016 3 Notes to the Pro-Forma Financial Statements 4 YANEX GROUP, INC. Pro-Forma Balance Sheets (unaudited) Yanex G |
|
| July 5, 2016 |
Exhibit 99.1 Proto-Script Financial Statements PROTO-SCRIPT PHARMACEUTICALS, CORP. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED DECEMBER 31, 2015 AND 2014 AND FOR THE THREE MONTHS ENDED MARCH 31, 2016 AND 2015 Contents Page Report of Independent Registered Public Accounting Firm 2 Consolidated Financial Statements: Consolidated Balance Sheets as of March 31, 2016 (unaudited) Dece |
|
| July 5, 2016 |
Exhibit 10.1 Shares Exchange Agreement SHARE EXCHANGE AGREEMENT This Share Exchange Agreement, with an effective date of June 29, 2016, (this ?Agreement?) by and among Yanex Group, Inc., a Nevada corporation (?YNXG?) and Proto-Script Pharmaceuticals, Corp., a California corporation (?PSPC?), and the sole shareholder of PSPC (?PSPC Shareholder?) as set forth on Schedule I hereto. For purposes of th |
|
| July 5, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 29, 2016 YANEX GROUP, INC. (Exact name of registrant as specified in its charter) Nevada 333-175146 99-0363803 (State or other jurisdiction (Commission File Number) (IRS Employer |
|
| June 27, 2016 |
Yanex Group PRELIMINARY 14C INFORMATION STATEMENT Preliminary 14C Information Statement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 17, 2016 |
Form 8-K Current Report SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 16, 2016 YANEX GROUP, INC. (Exact name of registrant as specified in its charter) Nevada 333-175146 99-0363803 (State or other jurisdiction (Commission File Number) (IR |
|
| June 10, 2016 |
Yanex Group YANEX GROUP, INC., 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [x] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 29, 2016 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE EXCHANGE ACT For the transition period from to Commission File Number: 333-175146 YANEX GROUP, INC. (Name of Small Business Iss |
|
| June 10, 2016 |
Yanex Group YANEX GROUP, INC., 10-Q (Quarterly Report) 10-Q 1 ynxg-2015113010q.htm YANEX GROUP, INC., 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [x] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2015 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE EXCHANGE ACT For the transition period from to Commission File Number: 333- |
|
| June 10, 2016 |
Yanex Group YANEX GROUP, INC., 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [x] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2015 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE EXCHANGE ACT For the transition period from to Commission File Number: 333-175146 YANEX GROUP, INC. (Name of Small Business Issue |
|
| May 24, 2016 |
Yanex Group YANEX 10K (Annual Report) 10-K 1 ynxg-2015053110k.htm YANEX 10K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [ x ] ANNUAL REPORT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2015 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 333-175 |
|
| October 9, 2015 |
Filed by OTC Filings Inc. - www.otcedgar.com - 1-866-832-FILE (3453) - Yanex Gorup, Inc. - Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 8, 2015 YANEX GROUP, INC. (Exact name of registrant as specified in its cha |
|
| October 9, 2015 |
EX-10.2 2 exhibit102.htm EXHIBIT 10.2 1 2 3 4 5 |
|
| August 28, 2015 |
Proto Script Pharmaceutical FORM NT 10-K Filed by OTC Filings Inc. - www.otcedgar.com - 1-866-832-FILE (3453) - Yanex Gorup, Inc. - Form NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response.... 2.50 SEC FILE NUMBER 333-175146 CUSIP NUMBER 98474L104 [ X ] Fo |
|
| July 16, 2015 |
COMMON STOCK PURCHASE AGREEMENT EX-10.1 2 exhibit101.htm EXHIBIT 10.1 COMMON STOCK PURCHASE AGREEMENT This Common Stock Purchase Agreement (the “Agreement”) made this 15th day of July, 2015, by and between, 2470992 Ontario, Inc. and 2470993 Ontario, Inc. (hereinafter, collectively, the “Buyer”) and Leonardo Correa Rodriguez (the “Seller”), regarding the purchase of shares of common stock of Yanex Group, Inc., a Nevada corporatio |
|
| July 16, 2015 |
Filed by OTC Filings Inc. - www.otcedgar.com - 1-866-832-FILE (3453) - Yanex Gorup, Inc. - Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 15, 2015 YANEX GROUP, INC. (Exact name of registrant as specified in its chart |
|
| April 15, 2015 |
Proto Script Pharmaceutical FORM NT 10-Q Filed by OTC Filings Inc. - www.otcedgar.com - 1-866-832-FILE (3453) - Yanex Gorup, Inc. - Form NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response.... 2.50 SEC FILE NUMBER 333-175146 CUSIP NUMBER 98474L104 [ ] Form |
|
| January 15, 2015 |
PSCR / Proto Script Pharmaceutical Corp. NT 10-Q - - FORM NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response.... 2.50 SEC FILE NUMBER 333-175146 CUSIP NUMBER 98474L104 [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ X ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period |
|
| October 15, 2014 |
PSCR / Proto Script Pharmaceutical Corp. NT 10-Q - - FORM NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response.... 2.50 SEC FILE NUMBER 333-175146 CUSIP NUMBER 98474L104 [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ X ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period |
|
| October 8, 2014 |
Silberstein Ungar, PLLC CPAs and Business Advisors Silberstein Ungar, PLLC CPAs and Business Advisors Phone (248) 203-0080 Fax (248) 281-0940 30600 Telegraph Road, Suite 2175 Bingham Farms, MI 48025-4586 www. |
|
| October 8, 2014 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) off The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2014 YANEX GROUP, INC. (Exact name of registrant as specified in charter) Nevada 333-175146 99-0363803 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| September 2, 2014 |
YNXG / Yanex Group, Inc. NT 10-K - - FORM NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response.... 2.50 SEC FILE NUMBER 333-175146 CUSIP NUMBER 98474L104 [ X ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period |
|
| August 15, 2014 |
8-K 1 form8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) off The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2014 YANEX GROUP, INC. (Exact name of registrant as specified in charter) Nevada 333-175146 99-0363803 (State or other jurisdiction of incorporation |
|
| April 15, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response.... 2.50 SEC FILE NUMBER 333-175146 CUSIP NUMBER 98474L104 [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ X ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period |
|
| January 17, 2014 |
Proto Script Pharmaceutical FORM 10-Q (Quarterly Report) Filed by OTC Filings Inc. - www.otcedgar.com - 1-866-832-FILE (3453) - Yanex Gorup, Inc. - Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2013 o TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE EXCHANGE ACT For the transitio |
|
| January 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response.... 2.50 SEC FILE NUMBER 333-175146 CUSIP NUMBER 98474L104 [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ X ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period |
|
| October 16, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response.... 2.50 SEC FILE NUMBER 333-175146 CUSIP NUMBER 98474L104 [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ X ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period |
|
| August 30, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response.... 2.50 SEC FILE NUMBER 333-175146 CUSIP NUMBER 98474L104 [ X ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period |
|
| January 15, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response.... 2.50 SEC FILE NUMBER 000-53447 CUSIP NUMBER 501736 102 [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ X ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period |
|
| August 30, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response.... 2.50 SEC FILE NUMBER 000-53447 CUSIP NUMBER 501736 102 [ X ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period |
|
| June 1, 2012 |
8-K 1 f8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) off The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2012 YANEX GROUP, INC. (Exact name of registrant as specified in charter) Nevada 333-175146 99-0363803 (State or other jurisdiction of incorporation) ( |
